Working in silos, change will not occur. WBC convenes with our Partners, Champions, and Sponsors to move faster together toward our action initiative goals.
Join us for Our Annual Action for Impact Summit!
WBC’s Annual Action for Impact Summit unites thousands of attendees on a fully interactive platform, enabling participants to network, connect, and exchange ideas, innovations, and impact in real time.
WOMEN CEO REPORT
Terrie Curran is CEO and President at Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal diseases. Previously, she was president, Global Inflammation and Immunology (I&I) Franchise and member of the Executive Committee at Celgene. She joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA® for moderate-to-severe plaque psoriasis. Prior to joining Celgene, she served as senior vice president and general manager, Global Womens Health at Merck & Co. She currently sits on the board of Myovant Sciences. Terrie holds graduate and bachelors degrees from the University of Technology Sydney.
